Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q2

4544.TEDINET S100S6Z0
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥134.1bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥17.7bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥17.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥20.7bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥284.6bnat 2023-09-30Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥287.2bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥134.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥157.2bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥37.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥15.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥7.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-12.332023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥273.872022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥175.632022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥273.842022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥85.1bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥85.0bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥83m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥40.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥35.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥15.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-09-30¥604m
—segment totalrevenue2022-04-01 → 2022-09-30¥139.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥134.1bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥19.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 524
ItemContextValueUnit
Increase decrease in other current liabilities ope cfPrior1YTDDuration-4465000000JPY
Increase decrease in other current liabilities ope cfCurrentYTDDuration-6302000000JPY
Other net ope cfPrior1YTDDuration-2892000000JPY
Other net ope cfCurrentYTDDuration-227000000JPY
Subtotal ope cfPrior1YTDDuration21717000000JPY
Subtotal ope cfCurrentYTDDuration-3856000000JPY
Income taxes paid refund ope cfPrior1YTDDuration-5849000000JPY
Income taxes paid refund ope cfCurrentYTDDuration9297000000JPY
Other net ope cf subtotalPrior1YTDDuration-95000000JPY
Other net ope cf subtotalCurrentYTDDuration81000000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration15772000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration5522000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-8102000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-4743000000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-3453000000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-2938000000JPY
Purchase of investments in subsidiaries inv cfPrior1YTDDuration-8273000000JPY
Purchase of investments in subsidiaries inv cfCurrentYTDDuration－JPY
Proceeds from collection of guarantee deposits inv cfPrior1YTDDuration61000000JPY
Proceeds from collection of guarantee deposits inv cfCurrentYTDDuration513000000JPY
Other net inv cfPrior1YTDDuration1099000000JPY
Other net inv cfCurrentYTDDuration-102000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-18668000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-7272000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration－JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration4000000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-1811000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-3700000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-0JPY
Purchase of treasury stock fin cfCurrentYTDDuration-986000000JPY
Cash dividends paid fin cfPrior1YTDDuration-3596000000JPY
Cash dividends paid fin cfCurrentYTDDuration-3601000000JPY
Repayments of finance lease obligations fin cfPrior1YTDDuration-2101000000JPY
Repayments of finance lease obligations fin cfCurrentYTDDuration-2167000000JPY
Other net fin cfPrior1YTDDuration77000000JPY
Other net fin cfCurrentYTDDuration399000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-7432000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-6055000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration1123000000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration716000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-9204000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-7089000000JPY
Cash and cash equivalentsPrior2YearInstant46479000000JPY
Cash and cash equivalentsPrior1YearInstant44185000000JPY
Cash and cash equivalentsPrior1QuarterInstant37275000000JPY
Cash and cash equivalentsCurrentQuarterInstant37096000000JPY
Salaries and bonuses sgaPrior1YTDDuration5508000000JPY
Salaries and bonuses sgaCurrentYTDDuration5614000000JPY
Provision for bonuses sgaPrior1YTDDuration2436000000JPY
Provision for bonuses sgaCurrentYTDDuration2211000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass